Navigation Links
NxStage to Report First Quarter 2009 Financial Results
Date:4/21/2009

LAWRENCE, Mass., April 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the first quarter ended March 31, 2009 on Friday, May 8, 2009 before the opening of the financial markets.

NxStage will also host a conference call at 9:00 a.m. Eastern Time on Friday, May 8, 2009 to discuss its first quarter financial results. To listen to the conference call, please dial 888-396-2369 (domestic) or 617-847-8710 (international). The passcode is 84522793. The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

A replay of the conference call will be available 3 hours after the start of the call through May 22, 2009. To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 17843987. An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include NxStage's plan to release its financial results on May 8, 2009. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, unexpected difficulty in closing the company's financial books for the quarter and other factors that are discussed in NxStage's Annual Report on Form 10-K for the year ended December 31, 2008 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Kristen K. Sheppard, Esq.VP, Investor Relations ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage to Present at the Cowen and Company 29th Annual Healthcare Conference
2. NxStage to Present at the JPMorgan Healthcare Conference
3. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
4. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
5. NxStage Announces Investor Conference Schedule
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. NxStage Medical to Present at William Blair Growth Stock Conference
8. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
9. NxStage Medical Announces Needle Supply Agreement with DaVita
10. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
11. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... NORWALK, Conn. , Dec. 2, 2016  The ... research presentations from the MMRF CoMMpass Study SM —the ... and accelerating precision medicine in multiple myeloma—will be presented ... (ASH) Annual Meeting & Exposition in San ... are helping to optimize treatment strategies, as well as ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
Breaking Biology Technology:
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of ... the most crucial aspects of recovery so we need to do it well. Inadequate ... including heart problems, high blood pressure, stroke, diabetes, and even cancer. Maybe ... find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... IRVINE, Calif. , Nov. 23, 2016 ... help endurance athletes and their trainers non-invasively measure ... Variability Index, Pulse Rate, and Respiration Rate in approximately ... Ember enables users easy and immediate access to key ... as part of a training regimen. ...
Breaking Biology News(10 mins):